Toyota Motor Corp. et al. v. Emerging Automotive LLC

IPR2024-00785

Toyota Motor Corp. filed a Director Review request in IPR2024-00785 concerning patent 10,407,026; the patent owner may respond within five business days.

Jurisdiction
US PTAB
Case Number
IPR2024-00785
Decision Date
23 April 2024
Filing Date
23 April 2024

Detailed Summary

In IPR2024-00785, challenger Toyota Motor Corp. and affiliates submitted a request for Director Review of the PTAB's decision regarding U.S. Patent No. 10,407,026 owned by Emerging Automotive LLC. The Director’s email instructs the patent owner to file a concise response limited to the issues raised, no more than five pages, within five business days, and prohibits new evidence or further briefing. The outcome of the Director Review request remains pending.

Practitioner Note

This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Toyota Motor Corp. et al. vs Emerging Automotive LLC is valuable context for structuring arguments or assessing risk in similar proceedings.

Related Cases

patentIPR2024-01405

Samsung Electronics Co., Ltd. et al.vsHarbor Island Dynamic, LLC

Court decision.

patentIPR2024-00665

FERVO ENERGY CO.vsOrmat Technologies, Inc.

The PTAB denied institution for FERVO ENERGY CO.'s IPR challenge against Ormat Technologies, Inc., finding that the petitioner failed to demonstrate a reasonable likelihood of prevailing. The denial was based on deficiencies in showing obviousness over prior art references like Rinaldi and Swenson.

patentIPR2025-00108

Jumio CorporationvsFaceTec, Inc.

Jumio Corporation successfully secured institution at the PTAB against FaceTec, Inc., establishing a reasonable likelihood of unpatentability for 24 claims related to facial recognition. The Board found that combinations of prior art references (Derakhshani/Tanii and Zhang/Tanii) rendered the claims obvious under 35 U.S.C. § 103.

patentIPR2024-00841

Abbott Diabetes Care Inc. et al.vsDexCom, Inc.

Abbott Diabetes Care and DexCom have entered into a settlement and jointly moved to terminate the inter partes review covering DexCom’s continuous glucose monitoring patent (U.S. 10,709,364). The Board has not yet decided the merits, satisfying the statutory requirements for termination under 35 U.S.C. §317(a).

patentIPR2024-01048

Apple Inc.vsS.M.R Innovations LTD et al.

The PTAB found the Petitioner (Apple Inc.) successfully demonstrated unpatentability of 12 claims against S.M.R Innovations LTD et al. The Board determined that the combination of prior art references taught or suggested all limitations for multiple challenged claims, particularly under § 103.

Arctic Invent — IP Strategy

Dealing with a patent challenge?

Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.

Talk to our patent team →

Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.

Strategy Consult

Facing a similar patent matter?

Arctic's litigation team uses precedent data like this to build winning arguments.

Get a Strategy Call